Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

Rapid detection of mycobacterial disease

Actiphage is unique as it is able to detect and identify live mycobacteria at a very early stage of infection, unlike other tests which rely on an immune response

Loading...

A major problem with many of the current diagnostics is they use the host immune response to diagnose infection. A key feature of mycobacteria is their ability to avoid the host’s immune system, resulting in inconsistent detection of infected individuals.

The alternative, gold-standard, diagnostic is culture, but this is also difficult as M. tuberculosis can take up to 12 weeks to culture.

So, a rapid, sensitive, alternative approach is required to understand, control and eradicate TB.

Actiphage uses a bacteriophage (literally: ‘bacteria eater’), a virus that is specific to a particular bacterium. The phage destroys the host cell, releasing its DNA, which can then be used as a target for detection and identification within hours.

Simple yes/no answer

The Actiphage assay combines phage technology (to detect only living bacteria) with traditional qPCR (which is extremely sensitive and specific for target DNA sequences) to create a new, highly sensitive and specific diagnostic assay that detects only live, disease-causing bacteria. 

It provides a simple yes/no answer – removing the confusion caused by current testing methods. 

Identifies a range of mycobacterial disease

Actiphage uses PCR primers to identify signature sequences known to be present in the genome of the bacteria. These sequences differ between the strains of the mycobacteria so the Actiphage test can be used to provide a number of mycobacterial tests.

Mycobacterial diseases detected

Actiphage also offers many benefits for diagnosis of human tuberculosis (M. tuberculosis).

In cattle, Actiphage can detect Mycobacterium bovis (M. bovis), which causes Bovine Tuberculosis (bTB) and M. avium subsp paratuberculosis (MAP), which causes Johne’s disease.

In addition, it can be used to identify both bTB and Johne’s disease in a range of different species, including sheep, deer and exotic captive species and also avian infections caused by M. avium.

 

 

Related content

Loading...
Actiphage use as a DIVA test

Actiphage optimised to detect MAP in humans and to support use as ‘DIVA’

June 1, 2022
This is the first time Actiphage has been used to detect MAP in a human blood sample and also to identify a live infection in a vaccinated goat.
Actiphage use as a DIVA test

Actiphage optimised to detect MAP in humans and to support use as ‘DIVA’

June 1, 2022
This is the first time Actiphage has been used to detect MAP in a human blood sample and also to...
ECCMID

Actiphage TB diagnostic finds live mycobacterium tuberculosis in the blood of people with incipient TB

April 23, 2022
A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live bacteria can be detected in the blood of people with incipient TB infection.
ECCMID

Actiphage TB diagnostic finds live mycobacterium tuberculosis in the blood of people with incipient TB

April 23, 2022
A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live...
mycobacteria

Bacteriophage shows promise for detection and treatment of tuberculosis

March 7, 2022
Bacteriophages, viruses that infect and kill bacteria, offer the potential of a powerful tool for detecting and treating mycobacterial infections such as tuberculosis (TB), authors of a review in the journal Microorganisms* have reported.
mycobacteria

Bacteriophage shows promise for detection and treatment of tuberculosis

March 7, 2022
Bacteriophages, viruses that infect and kill bacteria, offer the potential of a powerful tool for detecting and treating mycobacterial infections...
Tomas Richardson

Disruptive phage technology attracts top scientist to PBD Biotech

January 18, 2022
“PBD Biotech has developed an exciting and potentially disruptive technology that uses bacteriophage to improve the molecular diagnosis of tuberculosis” says Dr Tomas Richardson.
Tomas Richardson

Disruptive phage technology attracts top scientist to PBD Biotech

January 18, 2022
“PBD Biotech has developed an exciting and potentially disruptive technology that uses bacteriophage to improve the molecular diagnosis of tuberculosis”...
1 2 3 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More